Literature DB >> 29279949

Re-irradiation with curative intent in patients with squamous cell carcinoma of the head and neck: a national survey of usual practice on behalf of the Italian Association of Radiation Oncology (AIRO).

Marta Maddalo1, Pierluigi Bonomo2, Liliana Belgioia3, Almalina Bacigalupo3, Vittorio Donato4, Daniela Alterio5, Ester Orlandi6, Angela Argenone7, Anna Merlotti8, Daniela Musio9, Marianna Trignani10, Stefano Ursino11, Stefano Arcangeli4, Carlo Furlan12, Mattia Falchetto Osti13.   

Abstract

OBJECTIVE: To report the results of a national survey investigating the pattern of practice of curative re-irradiation (ReRT) for recurrent squamous cell carcinoma of the head and neck.
METHODS: In March 2016, a 22-item, 4-section questionnaire was sent to all Italian Radiation Oncology centers. Sections were focused on assessing the expertise level of each center and collecting specific information on reRT prescription modalities in the adjuvant and definitive settings.
RESULTS: Overall, 77 centers completed the survey. The majority (50/77, 64.9%) of participating radiation oncologists were senior consultants (> 10 years of experience). Of the responding centers, 63 (81.8%) performed curative ReRT, while 14 (18.1%) did not, mainly (5/14, 35.7%) due to the avoidance of severe toxicity. The use of adjuvant ReRT was reported by less than half of the interviewed radiation oncologists (36/77, 46.7%). In case of unresectable local recurrence, definitive ReRT was claimed to be adopted in 55/77 (71.4%) for non-nasopharyngeal and 47/77 (61%) for nasopharyngeal cancer. The preferred treatment technique was Intensity Modulated Radiation Therapy (IMRT) followed by Stereotactic Body Radiation Therapy (SBRT). When IMRT was applied, the most common (19/55 responders, 34.5%) selection of treatment volume consisted of the Gross Tumor Volume (GTV) + 0.5 cm margin to account for microscopic disease.
CONCLUSION: Despite the absence of definitive evidence-based recommendations, a possible consideration for ReRT in case of unresectable recurrent head and neck cancer was reported by over 80% of radiation oncologists taking part in the national survey.

Entities:  

Keywords:  Clinical practice guidelines; Head and Neck Cancer; Radiation therapy; Re-irradiation; Squamous cell carcinoma

Mesh:

Year:  2017        PMID: 29279949     DOI: 10.1007/s00405-017-4853-8

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  28 in total

1.  Initial experience of hypofractionated radiation retreatment with true beam and flattening filter free beam in selected case reports of recurrent nasopharyngeal carcinoma.

Authors:  Filippo Alongi; Elena Clerici; Sara Pentimalli; Pietro Mancosu; Marta Scorsetti
Journal:  Rep Pract Oncol Radiother       Date:  2012-08-10

2.  Reirradiation in head and neck recurrent or second primary tumor: efficacy, safety, and prognostic factors.

Authors:  Michela Buglione; Marta Maddalo; Ercole Mazzeo; Pierluigi Bonomo; Luigi Spiazzi; Alessio Bruni; Fabiola Paiar; Luca Triggiani; Daniela Greto; Laura Rubino; Lorenzo Livi; Filippo Bertoni; Stefano Maria Magrini
Journal:  Tumori       Date:  2015-06-15       Impact factor: 2.098

3.  Prospective trial of high-dose reirradiation using daily image guidance with intensity-modulated radiotherapy for recurrent and second primary head-and-neck cancer.

Authors:  Allen M Chen; D Gregory Farwell; Quang Luu; Suzan Cheng; Paul J Donald; James A Purdy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-12       Impact factor: 7.038

4.  Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.

Authors:  Sharon A Spencer; Jonathan Harris; Richard H Wheeler; Mitchell Machtay; Christopher Schultz; William Spanos; Marvin Rotman; Ruby Meredith; Kie-Kian Ang
Journal:  Head Neck       Date:  2008-03       Impact factor: 3.147

5.  Validation of nomogram-based prediction of survival probability after salvage re-irradiation of head and neck cancer.

Authors:  Naoto Shikama; Yu Kumazaki; Nobuhiro Tsukamoto; Takeshi Ebara; Soichi Makino; Takanori Abe; Mitsuhiko Nakahira; Masashi Sugasawa; Shingo Kato
Journal:  Jpn J Clin Oncol       Date:  2012-12-12       Impact factor: 3.019

6.  A nomogram to predict loco-regional control after re-irradiation for head and neck cancer.

Authors:  Nadeem Riaz; Julian C Hong; Eric J Sherman; Luc Morris; Matthew Fury; Ian Ganly; Tony J C Wang; Weji Shi; Suzanne L Wolden; Andrew Jackson; Richard J Wong; Zhigang Zhang; Shyam D Rao; Nancy Y Lee
Journal:  Radiother Oncol       Date:  2014-06-30       Impact factor: 6.280

7.  Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.

Authors:  Corey J Langer; Jonathan Harris; Eric M Horwitz; Nicos Nicolaou; Merrill Kies; Walter Curran; Stuart Wong; Kian Ang
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

8.  Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma.

Authors:  François Janot; Dominique de Raucourt; Ellen Benhamou; Christophe Ferron; Gilles Dolivet; René-Jean Bensadoun; Marc Hamoir; Bernard Géry; Morbize Julieron; Marine Castaing; Etienne Bardet; Vincent Grégoire; Jean Bourhis
Journal:  J Clin Oncol       Date:  2008-10-20       Impact factor: 44.544

9.  Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer.

Authors:  Eric F Lartigau; Emmanuelle Tresch; Juliette Thariat; Pierre Graff; Bernard Coche-Dequeant; Karen Benezery; Luis Schiappacasse; Marian Degardin; Pierre-Yves Bondiau; Didier Peiffert; Jean-Louis Lefebvre; Thomas Lacornerie; Andrew Kramar
Journal:  Radiother Oncol       Date:  2013-11-18       Impact factor: 6.280

10.  Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients.

Authors:  R De Crevoisier; J Bourhis; C Domenge; P Wibault; S Koscielny; A Lusinchi; G Mamelle; F Janot; M Julieron; A M Leridant; P Marandas; J P Armand; G Schwaab; B Luboinski; F Eschwege
Journal:  J Clin Oncol       Date:  1998-11       Impact factor: 44.544

View more
  1 in total

1.  Investigating the displacement of radio-active sources during gold-198 grain brachytherapy for hospitalized oral cancer patients.

Authors:  Masaru Konishi; Yuki Takeuchi; Katsumaro Kubo; Nobuki Imano; Ikuno Nishibuchi; Yuji Murakami; Kiichi Shimabukuro; Pongsapak Wongratwanich; Naoya Kakimoto; Yasushi Nagata
Journal:  J Contemp Brachytherapy       Date:  2022-03-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.